STERIS Plc (Ireland) 10-Q 11 Feb 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	3 Months Ended	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2018	Feb. 08, 2019
Entity Information [Line Items]
Entity Registrant Name		STERIS plc
Entity Central Index Key		1,624,899
Document Type		10-Q
Document Period End Date		Dec. 31, 2018
Amendment Flag		false
Document Fiscal Year Focus		2,019
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date		--03-31
Entity Current Reporting Status		Yes
Entity Small Business		false
Entity Emerging Growth Company		false
Entity Filer Category		Large Accelerated Filer
Entity Common Stock, Shares Outstanding			84,587,442

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Dec. 31, 2018	Mar. 31, 2018
Current assets:
Cash and cash equivalents	$ 224,906	$ 201,534
Accounts receivable (net of allowances of $10,161 and $12,472 respectively)	509,859	528,066
Inventories, net	227,626	205,731
Prepaid expenses and other current assets	58,132	54,326
Total current assets	1,020,523	989,657
Property, plant, and equipment, net	989,044	1,010,524
Intangible Assets, Net (Including Goodwill)	2,945,214	3,160,764
Other assets	51,609	39,389
Total assets	5,006,390	5,200,334
Current liabilities:
Accounts payable	136,723	135,866
Accrued income taxes	0	379
Accrued payroll and other related liabilities	79,598	94,000
Accrued expenses and other	181,698	168,217
Total current liabilities	398,019	398,462
Long-term indebtedness	1,246,308	1,316,001
Deferred income taxes, net	153,158	159,971
Other Liabilities, Noncurrent	96,598	108,600
Total liabilities	1,894,083	1,983,034
Commitments and contingencies (see Note 8)
Preferred shares, with GBP 0.10 par value; 100 shares authorized; 100 issued and outstanding	15	15
Common shares, with GBP 0.10 par value; GBP 17,006 shares in the aggregate par amount authorized; 84,570 shares issued; and 84,747 shares outstanding	2,018,045	2,048,037
Retained earnings	1,253,501	1,146,223
Accumulated other comprehensive income	(167,025)	11,685
Total shareholders' equity	3,104,536	3,205,960
Noncontrolling interest	7,771	11,340
Total equity	3,112,307	3,217,300
Total liabilities and equity	$ 5,006,390	$ 5,200,334

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) £ in Thousands, $ in Thousands	Dec. 31, 2018GBP (£)£ / sharesshares	Dec. 31, 2018USD ($)shares	Mar. 31, 2018GBP (£)£ / sharesshares	Mar. 31, 2018USD ($)shares
Allowance for Doubtful Accounts Receivable, Current | $		$ 10,161		$ 12,472
Preferred Stock, Shares Authorized	100,000	100,000	100,000	100,000
Preferred Stock, Shares Issued	100,000	100,000	100,000	100,000
Preferred Stock, Shares Outstanding	100,000	100,000	100,000	100,000
Preferred Stock, Par or Stated Value Per Share | £ / shares	£ 0.10		£ 0.10
Common Stock, Shares Authorized | £	£ 17,006		£ 17,006
Common Stock, Shares, Issued	84,570,000	84,570,000	84,747,000	84,747,000
Common Stock, Shares, Outstanding	84,570,000	84,570,000	84,747,000	84,747,000
Common Stock, Par or Stated Value Per Share | £ / shares	£ 0.10		£ 0.10

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Total revenues	$ 696,238	$ 661,900	$ 2,013,957	$ 1,904,023
Cost of revenues:
Total cost of revenues	409,241	383,683	1,173,246	1,103,642
Gross Profit	286,997	278,217	840,711	800,381
Operating expenses:
Selling, general, and administrative	176,099	159,664	496,817	469,879
Research and development	15,167	15,195	47,160	43,173
Restructuring Costs	26,147	78	26,147	156
Total operating expenses	217,413	174,937	570,124	513,208
Income from operations	69,584	103,280	270,587	287,173
Non-operating expenses, net:
Interest expense	10,879	12,461	34,014	37,610
Interest income and miscellaneous expense	945	(1,117)	503	(3,974)
Total non-operating expenses, net	11,824	11,344	34,517	33,636
Income before income tax expense	57,760	91,936	236,070	253,537
Income tax expense	9,334	(3,404)	39,871	35,538
Net Income	48,426	95,340	196,199	217,999
Less: Net Income Attributable to Noncontrolling Interest	568	559	893	682
Net income attributable to shareholders	$ 47,858	$ 94,781	$ 195,306	$ 217,317
Net income per common share [Abstract]
Basic	$ 0.57	$ 1.12	$ 2.31	$ 2.55
Diluted	0.56	1.11	2.28	2.53
Cash dividends declared per common share outstanding	$ 0.34	$ 0.31	$ 0.99	$ 0.90
Service [Member]
Revenues:
Total revenues	$ 368,599	$ 352,439	$ 1,092,869	$ 1,034,400
Cost of revenues:
Cost of Goods and Services Sold	227,012	221,072	672,308	645,175
Product [Member]
Revenues:
Total revenues	327,639	309,461	921,088	869,623
Cost of revenues:
Cost of Goods and Services Sold	$ 182,229	$ 162,611	$ 500,938	$ 458,467

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Consolidated Statements of Comprehensive Income [Abstract]
Net Income	$ 48,426	$ 95,340	$ 196,199	$ 217,999
Less: Net Income Attributable to Noncontrolling Interest	568	559	893	682
Net income attributable to shareholders	47,858	94,781	195,306	217,317
Other comprehensive (loss) income
Unrealized loss on available for sale securities, (net of taxes of $0, $693, $0 and $1,179 respectively)	0	2,738	0	4,509
Amortization of pension and postretirement benefits plans costs, (net of taxes of $169, $250, $507 and $749, respectively)	(415)	(404)	(1,238)	(1,212)
Change in cumulative foreign current translation adjustment	(39,830)	22,742	(175,502)	182,422
Total other comprehensive (loss) income	(40,245)	25,076	(176,740)	185,719
Comprehensive income	7,613	119,857	18,566	403,036
Other comprehensive (loss) income (parenthetical)
Unrealized loss on available for sale securities, tax	0	693	0	1,179
Amortization of pension and postretirement benefits plans costs, tax	$ 169	$ 250	$ 507	$ 749

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands		9 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Net Income		$ 196,199	$ 217,999
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, depletion, and amortization		175,658	133,855
Deferred income taxes		2,218	(27,318)
Share-based compensation		18,357	17,041
(Gain) loss on the disposal of property, plant, and equipment, and intangibles, net		(208)	819
Loss on sale of businesses, net	[1]	(508)	12,538
Other items		(9,767)	11,410
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable, net		9,318	15,149
Inventories, net		(32,083)	(21,567)
Other current assets		(5,816)	(4,843)
Accounts payable		5,119	(10,601)
Accruals and other, net		2,092	(16,627)
Net cash provided by operating activities		360,579	327,855
Investing activities:
Purchases of property, plant, equipment, and intangibles, net		(113,236)	(113,511)
Proceeds from the sale of property, plant, equipment, and intangibles		5,563	2,094
Proceeds from Divestiture of Businesses		(196)	8,907
Purchase of investments		(4,955)	0
Acquisition of businesses, net of cash acquired		(13,313)	(46,323)
Payments for (Proceeds from) Other Investing Activities		(13,425)	0
Net cash used in investing activities		(139,562)	(148,833)
Financing activities:
Payments on long-term obligations		(85,000)	(22,500)
Proceeds (Payments) under credit facilities, net		35,416	(58,729)
Deferred financing fees and debt issuance costs		(298)	(44)
Acquisition related deferred or contingent consideration		(1,277)	(2,064)
Repurchases of ordinary shares		(56,254)	(43,851)
Cash dividends paid to ordinary shareholders		(83,750)	(76,633)
Stock option and other equity transactions, net		7,355	8,005
Net cash used in financing activities		(183,808)	(195,816)
Effect of exchange rate changes on cash and cash equivalents		(13,837)	17,720
Increase (decrease) in cash and cash equivalents		23,372	926
Cash and cash equivalents at beginning of period		201,534	282,918
Cash and cash equivalents at end of period		$ 224,906	$ 283,844
[1]	For more information regarding our recent acquisitions and divestitures see Note 17 titled, "Business Acquisitions and Divestitures", as well as our Annual Report on Form 10-K for the year ended March 31, 2018, dated May 30, 2018.

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies(Notes)	9 Months Ended
	Dec. 31, 2018
Notes To Financial Statements [Abstract]
Nature of Operations	Nature of Operations and Summary of Significant Accounting Policies Nature of Operations STERIS plc (“Parent”) was organized in 2014 under the name Solar New HoldCo Limited as a private limited company for the purpose of effecting under the laws of England and Wales the combination (“Combination”) of STERIS Corporation, an Ohio corporation (“Old STERIS”), and Synergy Health plc, a public limited company organized under the laws of England and Wales (“Synergy”). Effective November 2, 2015 the Parent was re-registered as a public company under the name STERIS plc and the Combination closed. As a result of the Combination closing, STERIS plc became the ultimate parent company of Old STERIS and Synergy. Synergy has been re-registered under the name of Synergy Health Limited. The Company is a leading provider of infection prevention and other procedural products and services. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal ("GI") endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory testing services, on-site and off-site reprocessing, and capital equipment products, such as sterilizers and surgical tables, and connectivity solutions such as operating room (“OR”) integration. Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2018 dated May 30, 2018 . The Consolidated Balance Sheet at March 31, 2018 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2018 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2019. Revenue Recognition and Associated Liabilities We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018 using the modified retrospective approach to contracts that were not completed as of April 1, 2018. Under this standard, certain capital equipment contracts are comprised of a single performance obligation, resulting in the deferral of the corresponding capital equipment revenue and cost of revenues until installation is complete. Previously, these capital equipment revenues and cost of revenues were recognized based upon shipping terms. We recorded a cumulative effect adjustment in the beginning of fiscal 2019 to Retained earnings of $5,637 , based on the current terms and conditions for certain open capital equipment contracts as of March 31, 2018. The impact of the adoption of this standard on our Consolidated Balance Sheets at December 31, 2018 is reflected in the table below. The adoption of this standard did not have a material impact on our Consolidated Statements of Income for the quarter-to-date and year-to-date periods ending December 31, 2018 . Comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. As Reported December 31, Total ASC 605 December 31, Balance Sheet 2018 Adjustments 2018 Total assets $ 5,006,390 $ (7,714 ) $ 4,998,676 Total liabilities 1,894,083 (13,809 ) 1,880,274 Total equity 3,112,307 6,095 3,118,402 Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2018 , assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements. Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to certain capital equipment products is deferred until installation is complete as the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare Products and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancelable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Healthcare Specialty Services segment, revenues relate primarily to outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2019, we recognized revenue of $25,590 that was included in our contract liability balance at the beginning of the period. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances. Service Liabilities Payments received in advance of performance for cancelable preventative maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Prior to the adoption of Accounting Standards Codification ("ASC") 606, these amounts were included in Deferred revenues. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31, 2018 , the transaction price allocated to remaining performance obligations was approximately $780,000 . We expect to recognize approximately 53% of the transaction price within one year and approximately 39% beyond one year. The remainder has yet to be scheduled for delivery. Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards impacting or that may impact the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2014-09, "Revenue from Contracts with Customers" and subsequently issued amendments May 2014 The standard replaced existing revenue recognition standards and significantly expands the disclosure requirements for revenue arrangements. First Quarter Fiscal 2019 Additional information is disclosed in Footnote 1 under the heading, "Revenue Recognition and Associated Liabilities". ASU 2016-01, "Financial Instruments - Overall - Recognition and Measurement of Financial Assets and Liabilities" (Subtopic 825-10) January 2016 The standard changed how equity investments are measured and presented changes in the fair value of financial liabilities measured under the fair value option. Presentation and disclosure requirements for financial instruments were also affected. Entities are required to measure equity investments that do not result in consolidation and are not recorded under the equity method at fair value with changes in fair value recognized in net income. The standard clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. First Quarter Fiscal 2019 We adopted the standard on a modified retrospective basis at the beginning of fiscal 2019 and we recorded a cumulative effect adjustment to our opening retained earnings balance of $1,970 that increased retained earnings and decreased accumulated other comprehensive income. ASU 2016-15, "Statement of Cash Flows" (Topic 230) August 2016 This standard provides guidance on the following specific cash flow issues: Debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, beneficial interests in securitization transactions, and separately identifiable cash flows and application of the predominance principle. First Quarter Fiscal 2019 We adopted this standard effective April 1, 2018. The impact will depend on the future occurrence of the relevant transactions or conditions addressed by the standard. ASU 2016-16, "Income Taxes, Intra-Entity Transfers of Assets Other Than Inventory" (Topic 740) October 2016 The standard improves the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. The new standard requires the recognition of income tax consequences resulting from an intra-entity transfer of an asset other than inventory when the transfer occurs. First Quarter Fiscal 2019 We adopted this standard effective April 1, 2018 with no material impact to our Consolidated Balance Sheets. The impact to our Consolidated Statements of Income will depend on the value of future intra-entity transfers. ASU 2017-01 "Clarifying the Definition of a Business" January 2017 The standard update narrows the definition of a business by providing a screen to determine when an integrated set of assets and activities is not a business. The screen specifies that an integrated set of assets and activities is not a business if substantially all of the fair value of the gross assets acquired or disposed of is concentrated in a single or a group of similar identifiable assets. First Quarter Fiscal 2019 We adopted this standard effective April 1, 2018. The impact will depend on the future occurrence of the relevant transactions or conditions addressed by the standard. ASU 2017-07 "Compensation - Retirement Benefits - Improving the Presentation of Net Periodic Pension and Net Periodic Postretirement Benefit Cost" (Topic 715) March 2017 This standard requires that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside the subtotal of income from operations, if one is presented. First Quarter Fiscal 2019 We retrospectively adopted the standard in the first quarter of fiscal 2019. Prior periods have been recast for the adoption of this standard. Changes have been reflected in the Cost of Revenues, Selling, general and administrative expense, and Interest income and miscellaneous expense lines of our Consolidated Statements of Income. Amounts are not considered material for additional disclosure. ASU 2017-09 "Compensation - Stock Compensation" (Topic 718) May 2017 The standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. First Quarter Fiscal 2019 We adopted this standard effective April 1, 2018. The impact will depend on the future occurrence of the relevant terms or conditions addressed by the standard. Standards that have not yet been adopted ASU 2016-02, "Leases" (Topic 842) February 2016 The standard will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted. N/A We are currently evaluating the impact that the standard will have on our consolidated financial statements. We are also evaluating our lease portfolio, software packages, process and policy change requirements. We expect to adopt this standard using the additional, optional transition method, the package of transitional practical expedients relating to the identification, classification and initial direct costs of leases, and the transitional practical expedient for the treatment of existing land easements. We anticipate that most of our operating leases will result in the recognition of additional assets and corresponding liabilities in our Consolidated Balance Sheet, however we do not expect the standard to have a material impact on our financial position. The actual impact will depend on our lease portfolio at the time of adoption. For more information regarding our total operating lease commitments refer to Note 5, "Property, Plant and Equipment" of our Annual Report on Form 10-K for the year ended March 31, 2018 dated May 30, 2018. ASU 2016-13, "Measurement of Credit Losses on Financial Instruments" June 2016 The standard requires a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard is effective for annual periods beginning after December 15, 2019. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. ASU 2017-12 "Targeted Improvements to Accounting for Hedging Activities" (Topic 815) August 2017 The standard provides targeted improvements to accounting for hedging activities by expanding an entity’s ability to hedge non-financial and financial risk components and reduce complexity in fair value hedges of interest rate risk. The guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally requires the entire change in the fair value of a hedging instrument to be presented in the same income statement line as the hedged item. The guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted in any interim period after issuance of the standard. The standard should be applied using a modified retrospective approach for cash flow and net investment hedge relationships that exist on the date of adoption, and prospectively for presentation and disclosure requirements. N/A We do not expect this standard to have a material impact on our consolidated financial statements. ASU 2018-02 "Income Statement - Reporting Comprehensive Income" (Topic 220) February 2018 The standard allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act ("TCJA") and requires certain disclosures about stranded tax effects. The underlying guidance requiring that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. This standard is effective for fiscal years beginning after December 15, 2018 and interim periods within those years. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement” August 2018 The standard modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements as it modifies disclosure requirements only. ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans" August 2018 The standard modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans. The standard also clarifies disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation. The standard is effective for fiscal years ending after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements as it modifies disclosure requirements only. ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract" August 2018 The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for fiscal years ending after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2018 dated May 30, 2018 . With the exception of the adoption of ASU 2014-09, as discussed in Footnote 1 under the heading, "Revenue Recognition and Associated Liabilities", our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2018 .

Business Acquisitions and Dives

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)	9 Months Ended
	Dec. 31, 2018
Business Acquisitions and Divestitures [Abstract]
Business acquisitions and divestitures	Business Acquisitions and Divestitures Fiscal 2019 During the third quarter of fiscal 2019, we completed a minor purchase to expand our service offerings in the Applied Sterilization Technologies segment. The total purchase price was $13,313 , which was financed with both cash on hand and with credit facility borrowings. Purchase price allocations will be finalized within a measurement period not to exceed one year from closing. Fiscal 2018 During fiscal 2018, we completed several minor purchases which continued to expand our product offerings in the Healthcare Products, Healthcare Specialty Services and Applied Sterilization Technologies segments. The aggregate purchase price associated with these transactions was approximately $52,900 , ( $51,600 during the first nine months of fiscal 2018), net of cash acquired and including potential contingent consideration of $5,322 . The purchase price for the acquisitions was financed with both cash on hand and with credit facility borrowings. Purchase price allocations are finalized within a measurement period not to exceed one year from closing. Any provisional adjustments recorded were not material. On November 20, 2017, we sold our Synergy Health Healthcare Consumable Solutions ("HCS") business to Vernacare. Annual revenues for the HCS business were approximately $40,000 and were included in the Healthcare Products segment. We recorded proceeds of approximately $9,058 , net of cash divested and including a working capital adjustment. We also recognized a pre-tax loss on the sale of approximately $13,500 in Selling, general, and administrative expense in our March 31, 2018 Consolidated Statement of Income.

Inventories, Net (Notes)

Inventories, Net (Notes)	9 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventories, Net	Inventories, Net We use the last-in, first-out (“LIFO”) and first-in, first-out (“FIFO”) cost methods to value inventory. Inventory valued using the LIFO cost method is stated at the lower of cost or market. Inventory valued using the FIFO cost method is stated at the lower of cost or net realizable value. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: December 31, March 31, Raw materials $ 88,413 $ 83,741 Work in process 31,238 34,904 Finished goods 146,121 124,005 LIFO reserve (17,800 ) (17,280 ) Reserve for excess and obsolete inventory (20,346 ) (19,639 ) Inventories, net $ 227,626 $ 205,731

Property, Plant and Equipment (

Property, Plant and Equipment (Notes)	9 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 64,000 $ 55,417 Buildings and leasehold improvements 427,889 449,316 Machinery and equipment 591,905 575,607 Information systems 156,674 145,726 Radioisotope 486,866 476,578 Construction in progress (1) 130,142 87,745 Total property, plant, and equipment 1,857,476 1,790,389 Less: accumulated depreciation and depletion (868,432 ) (779,865 ) Property, plant, and equipment, net $ 989,044 $ 1,010,524 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Notes)

Debt (Notes)	9 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Debt	Debt Indebtedness was as follows: December 31, March 31, Credit Agreement $ 364,853 $ 331,206 Private Placement Notes 884,409 988,190 Deferred financing costs (3,008 ) (3,395 ) Other 54 — Total long term debt $ 1,246,308 $ 1,316,001 Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2018 , dated May 30, 2018 .

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information (Notes)	9 Months Ended
	Dec. 31, 2018
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 26,065 $ 30,270 Accrued vacation/paid time off 11,514 11,011 Accrued bonuses 23,628 31,716 Accrued employee commissions 14,681 17,168 Other postretirement benefit obligations-current portion 1,907 1,906 Other employee benefit plans obligations-current portion 1,803 1,929 Total accrued payroll and other related liabilities $ 79,598 $ 94,000 Accrued expenses and other: Deferred revenues $ 58,827 $ 31,621 Service liabilities 41,549 43,077 Self-insured risk reserves-current portion 8,082 7,349 Accrued dealer commissions 14,016 16,121 Accrued warranty 7,116 6,872 Asset retirement obligation-current portion 1,763 1,798 Other 50,345 61,379 Total accrued expenses and other $ 181,698 $ 168,217 Other liabilities: Self-insured risk reserves-long-term portion $ 15,008 $ 15,008 Other postretirement benefit obligations-long-term portion 10,350 12,194 Defined benefit pension plans obligations-long-term portion 24,146 29,407 Other employee benefit plans obligations-long-term portion 2,551 3,221 Accrued long-term income taxes 16,546 18,922 Asset retirement obligation-long-term portion 9,484 9,841 Other 18,513 20,007 Total other liabilities $ 96,598 $ 108,600

Income Tax Expense (Notes)

Income Tax Expense (Notes)	9 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax Expense	Income Tax Expense The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The TCJA reduces the U.S. federal corporate income tax rate from 35.0% to 21.0% , requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings. The Company applied the guidance in Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cut and Jobs Act when accounting for the enactment-date effects of the TCJA. At December 31, 2018, the Company has completed its accounting for the tax effects of the TCJA. During the nine months ended December 31, 2018, the Company recorded an immaterial favorable adjustment to the provisional amounts recorded as of March 31, 2018 for remeasurement of the Company’s deferred tax balances and the one-time transition tax. The TCJA also subjects a U.S. shareholder to current tax on global intangible low-taxed income (“GILTI”) earned by certain foreign subsidiaries and allows a benefit for foreign-derived intangible income (“FDII”). The Company has made sufficient progress in its calculation to reasonably estimate the tax impact related to GILTI and FDII for the year ended March 31, 2019 and included it in the estimated annual effective tax rate. The impact of GILTI and FDII was not significant for the first nine months ended December 31, 2018 . With the closure of the SAB 118 period, the Company is confirming its policy decision to treat GILTI as a period expense in the period the tax is incurred. We consider the tax expense recorded for the TCJA to be complete at this time. However, it is possible that additional legislation, regulations and/or guidance may be issued in the future that may result in additional adjustments to the tax expense recorded related to the TCJA. We will continue to monitor and assess the impact of any new developments. The effective income tax rates for the three month periods ended December 31, 2018 and 2017 were 16.2% and (3.7)% , respectively. The effective income tax rates for the nine month periods ended December 31, 2018 and 2017 were 16.9% and 14.0% , respectively. The fiscal 2019 periods were favorably impacted by discrete item adjustments. The lower effective tax rates in the fiscal 2018 periods are primarily attributable to the enactment of the TCJA, resulting in a decrease in the U.S. federal statutory tax rate. Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as non-United States jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2016 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2012. We remain subject to tax authority audits in various jurisdictions wherever we do business. We do not expect the results of these examinations to have a material adverse effect on our consolidated financial statements.

Contingencies (Notes)

Contingencies (Notes)	9 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. On May 31, 2012, our Albert Browne Limited subsidiary received a warning letter from the FDA regarding chemical indicators manufactured in the United Kingdom. These devices are intended for the monitoring of certain sterilization and other processes. The FDA warning letter states that the agency has concerns regarding operational business processes. We do not believe that the FDA's concerns are related to product performance, or that they result from Customer complaints. We have reviewed our processes with the agency and finalized our remediation measures, and are awaiting FDA reinspection. We do not currently believe that the impact of this event will have a material adverse effect on our financial results. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2018, dated May 30, 2018: Item 1 titled “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factors” in Item 1A titled "Product related regulations and claims". From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q.

Business Segment Information (N

Business Segment Information (Notes)	9 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information We operate and report our financial information in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. Corporate, which is presented separately, contains costs that are associated with being a publicly traded company and certain other corporate costs. Our Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. Our Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, and instrument and scope repairs. Our Life Sciences segment offers consumable products, equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and capital equipment. Our Applied Sterilization Technologies segment offers contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. In fiscal 2019, we ceased the allocation of certain corporate costs to our segments to align with internal management measures. The prior period operating income measures have been recast for comparability. Segment income is calculated as the segment’s gross profit less direct costs and indirect costs if the resources are dedicated to a single segment. Corporate costs include corporate and administrative functions, public company costs, legacy post-retirement benefits, and certain services and facilities related to distribution and research and development that are shared by multiple segments. Adjustments include acquisition related costs, amortization of acquired intangibles, restructuring costs and other charges that management believes may or may not recur with similar materiality or impact on operating income in future periods. Management believes that by adjusting for these items they gain better insight and greater transparency into the operating performance of the segments, thus aiding them in more meaningful financial trend analysis and operational decision making. For the three and nine months ended December 31, 2018 , revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2018 , dated May 30, 2018 . Financial information for each of our segments is presented in the following table: Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 Revenues: Healthcare Products $ 338,264 $ 324,895 $ 951,779 $ 916,053 Healthcare Specialty Services 127,761 117,389 374,564 346,934 Life Sciences 93,451 90,895 275,571 261,291 Applied Sterilization Technologies 136,762 128,721 412,043 379,745 Total revenues $ 696,238 $ 661,900 $ 2,013,957 $ 1,904,023 Segment operating income: Healthcare Products $ 82,820 $ 81,502 $ 217,011 $ 207,787 Healthcare Specialty Services 16,007 13,720 44,422 44,014 Life Sciences 33,129 31,245 96,260 89,418 Applied Sterilization Technologies 54,798 48,191 164,417 144,713 Corporate (42,025 ) (38,140 ) (135,053 ) (122,147 ) Total segment operating income $ 144,729 $ 136,518 $ 387,057 $ 363,785 Less: Adjustments Restructuring charges (1) $ 35,243 $ 78 $ 35,243 $ 156 Amortization of acquired intangible assets (2) (3) 33,894 16,700 68,907 50,173 Acquisition and integration related charges (4) 1,816 4,428 6,197 11,850 (Gain) on fair value adjustment of acquisition related contingent consideration (2) — — (842 ) — Net (gain) loss on divestiture of businesses (2) (1,170 ) 11,405 (508 ) 12,538 Amortization of property "step up" to fair value (2) 615 627 1,840 1,895 Redomiciliation costs (5) 4,747 — 5,633 — Total operating income $ 69,584 $ 103,280 $ 270,587 $ 287,173 (1) For more information regarding restructuring see Note 2 titled, "Restructuring". (2) For more information regarding our recent acquisitions and divestitures see Note 17 titled, "Business Acquisitions and Divestitures", as well as our Annual Report on Form 10-K for the year ended March 31, 2018 , dated May 30, 2018 . (3) We evaluate the recoverability of indefinite-lived assets annually during the third quarter, or when evidence of potential impairment exists. During the third quarter of fiscal 2019, management adopted a branding strategy that included phasing out the usage of a tradename associated with certain products in the Healthcare Products business segment. As a result, management recorded an impairment charge of $16,249 , which is included within the Selling, general, and administrative line of the Consolidated Statements of Income. The remaining fair value of the asset was calculated using the income approach (the relief from royalty method). The remaining fair value was not material and will be amortized over the asset's remaining useful life. Fair value calculated using this approach is classified within Level 3 of the fair value hierarchy and requires several assumptions. (4) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (5) Costs incurred in connection with the proposal to redomicile. For more information see Note 19 titled, "Proposal to Redomicile ". Additional information regarding our revenue is disclosed in the following tables: Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 Healthcare Products: Capital equipment $ 143,180 $ 134,196 $ 384,086 $ 359,196 Consumables 107,451 106,406 309,545 310,938 Service 87,633 84,293 258,148 245,919 Total Healthcare Products Revenues $ 338,264 $ 324,895 $ 951,779 $ 916,053 Total Healthcare Specialty Services Revenues $ 127,761 $ 117,389 $ 374,564 $ 346,934 Life Sciences: Capital equipment $ 23,363 $ 25,337 $ 72,289 $ 67,093 Consumables 41,157 37,875 119,844 113,833 Service 28,931 27,683 83,438 80,365 Total Life Sciences Revenues $ 93,451 $ 90,895 $ 275,571 $ 261,291 Applied Sterilization Technologies Service Revenues $ 136,762 $ 128,721 $ 412,043 $ 379,745 Total Revenues $ 696,238 $ 661,900 $ 2,013,957 $ 1,904,023 Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 Revenues: United Kingdom $ 46,067 $ 50,902 $ 138,074 $ 158,211 United States 494,328 465,228 1,423,101 1,334,895 Other locations 155,843 145,770 452,782 410,917 Total Revenues $ 696,238 $ 661,900 $ 2,013,957 $ 1,904,023

Shares and Preferred Shares (No

Shares and Preferred Shares (Notes)	9 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share	Ordinary shares We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, Denominator (shares in thousands): 2018 2017 2018 2017 Weighted average shares outstanding—basic 84,540 85,004 84,587 85,097 Dilutive effect of share equivalents 901 715 889 672 Weighted average shares outstanding and share equivalents—diluted 85,441 85,719 85,476 85,769 Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended December 31, Nine Months Ended December 31, (shares in thousands) 2018 2017 2018 2017 Number of share options 435 294 331 426 Preferred Shares Pursuant to an engagement letter dated October 23, 2015, we issued 100,000 preferred shares, par value of £0.10 each, for an aggregate consideration of approximately $15 , in satisfaction of debt owed to a service provider. The holders of the preferred shares are entitled to a fixed cumulative preferential annual dividend of 5 percent on the amount paid periodically on the preferred shares respectively held by them. On a return of capital of the Company whether on liquidation or otherwise, the holders of the preferred shares shall be entitled to receive the sum of £0.10 per preferred share plus any accrued but unpaid dividends out of the assets of the Company available for distribution to its shareholders, but will not be entitled to any further participation in the assets of the Company. The holders of the preferred shares have no right to attend, speak or vote, whether in person or by proxy, at any general meeting of the Company or any meeting of a class of members of the Company in respect of the preferred shares and are not entitled to receive any notice of meetings.

Repurchases of Shares (Notes)

Repurchases of Shares (Notes)	9 Months Ended
	Dec. 31, 2018
Notes To Financial Statements [Abstract]
Repurchases of shares	Repurchases of Ordinary Shares On August 9, 2016, the Company announced that its Board of Directors had authorized the purchase of up to $300 million of our ordinary shares. We may enter into share repurchase contracts until August 2, 2021 to effect these purchases. Shares may be repurchased from time to time through open market transactions, including 10b5-1 plans. The repurchase program may be suspended or discontinued at any time. During the first nine months of fiscal 2019 , we repurchased 445,700 of our ordinary shares for the aggregate amount of $47,331 pursuant to this authorization. During the first nine months of fiscal 2019 , we obtained 110,445 of our ordinary shares in the aggregate amount of $8,151 in connection with share based compensation award programs.

Share-Based Compensation (Notes

Share-Based Compensation (Notes)	9 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Compensation Committee of the Board of Directors, or the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares. Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted in fiscal 2019, 110% of the market price on the date of grant, subject to the terms of the option plan and agreements. Generally, one-fourth of the stock options granted become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each full year of employment after the grant date. As of December 31, 2018 , 4,401,238 shares remained available for grant under the long-term incentive plan. The fair value of stock option awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2019 and 2018: Fiscal 2019 Fiscal 2018 Risk-free interest rate 2.64% 2.01% Expected life of options 6.2 years 5.7 years Expected dividend yield of stock 1.47% 1.58% Expected volatility of stock 19.91% 22.08% The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.37% and 2.25% was applied in fiscal 2019 and 2018 , respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2018 2,021,662 $ 58.56 Granted 436,121 114.49 Exercised (191,995 ) 40.05 Forfeited (17,740 ) 79.91 Outstanding at December 31, 2018 2,248,048 $ 70.83 6.8 years $ 84,291 Exercisable at December 31, 2018 1,307,946 $ 56.03 5.5 years $ 66,631 We estimate that 919,536 of the non-vested stock options outstanding at December 31, 2018 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $106.85 closing price of our ordinary shares on December 31, 2018 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares. The total intrinsic value of stock options exercised during the first nine months of fiscal 2019 and fiscal 2018 was $13,773 and $12,495 , respectively. Net cash proceeds from the exercise of stock options were $7,534 and $9,080 for the first nine months of fiscal 2019 and fiscal 2018 , respectively. The weighted average grant date fair value of stock option grants was $18.12 and $15.51 for the first nine months of fiscal 2019 and fiscal 2018 , respectively. Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of December 31, 2018 and 2017 was $692 and $1,733 , respectively. A summary of the non-vested restricted share and restricted share unit activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2018 763,201 35,431 $ 68.85 Granted 177,558 19,858 104.84 Vested (233,095 ) (21,540 ) 62.12 Forfeited (30,469 ) — 76.62 Non-vested at December 31, 2018 677,195 33,749 $ 80.72 Restricted shares and restricted share units granted are valued based on the closing stock price at the grant date. The value of restricted shares and restricted share units that vested during the first nine months of fiscal 2019 was $15,817 . As of December 31, 2018 , there was a total of $43,979 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plan. We expect to recognize the cost over a weighted average period of 2.19 years .

Financial and Other Guarantees(

Financial and Other Guarantees(Notes)	9 Months Ended
	Dec. 31, 2018
Product Warranties Disclosures [Abstract]
Product Warranty Disclosure	Financial and Other Guarantees We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the first nine months of fiscal 2019 were as follows: Warranties Balance, March 31, 2018 $ 6,872 Warranties issued during the period 8,393 Settlements made during the period (8,149 ) Balance, December 31, 2018 $ 7,116

Deritvatives and Hedging (Notes

Deritvatives and Hedging (Notes)	9 Months Ended
	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure	Derivatives and Hedging From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. During the first quarter of fiscal 2019, we also entered into forward foreign currency contracts in order to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature during fiscal 2019. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At December 31, 2018 , we held foreign currency forward contracts to buy 152.2 million Mexican pesos and 8.9 million Canadian dollars; and to sell 2.0 million euros. At December 31, 2018 , we held commodity swap contracts to buy 789.9 thousand pounds of nickel. Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location December 31, 2018 March 31, 2018 December 31, 2018 March 31, 2018 Prepaid & Other $ 267 $ 187 $ — $ — Accrued expenses and other — — 462 — The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) recognized in income Amount of gain (loss) recognized in income Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 Foreign currency forward contracts Selling, general and administrative $ (488 ) $ (842 ) $ (100 ) $ (1,358 ) Commodity swap contracts Cost of revenues $ (252 ) $ 200 $ (283 ) $ 226 Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $52,253 at December 31, 2018 . These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Fair Value Measurements (Notes)

Fair Value Measurements (Notes)	9 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at December 31, 2018 and March 31, 2018 : Fair Value Measurements Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 December 31 March 31 December 31 March 31 December 31 March 31 December 31 March 31 Assets: Cash and cash equivalents $ 224,906 $ 201,534 $ 224,906 $ 201,534 $ — $ — $ — $ — Forward and swap contracts (1) 267 187 — — 267 187 — — Equity Investments (2) $ 11,824 12,961 11,824 12,961 — — — — Other investments 2,010 3,421 1 2,010 3,421 — — — — — — Liabilities: Forward and swap contracts (1) $ 462 $ — $ — $ — $ 462 $ — $ — $ — Deferred compensation plans (2) 1,505 1,694 1,505 1,694 — — — — Long term debt (3) $ 1,246,308 1,316,001 — — 1,227,345 1,305,181 — — Contingent consideration obligations (4) 5,947 8,068 — — — — 5,947 8,068 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Beginning in fiscal 2019, changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the third quarter and first nine months of fiscal 2019, we recorded losses of $2,154 and $4,663 respectively, related to these investments. (3) We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2018 are summarized as follows: Contingent Consideration Balance at March 31, 2018 $ 8,068 Payments (725 ) Reductions and adjustments (1,415 ) Currency translation adjustments 19 Balance at December 31, 2018 $ 5,947

Reclassifications out of Accumu

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes)	9 Months Ended
	Dec. 31, 2018
Reclassifications out of AOCI [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2018 and 2017 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Currency Translation (3) Total Accumulated Other Comprehensive Income Three Months Nine Months Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ — $ 1,970 $ (7,565 ) $ (6,742 ) $ (119,215 ) $ 16,457 $ (126,780 ) $ 11,685 Other Comprehensive Income (Loss) before reclassifications — — 148 452 (39,830 ) (175,502 ) (39,682 ) (175,050 ) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) — — (563 ) (1,690 ) — — (563 ) (1,690 ) Net current-period Other Comprehensive Income (Loss) — — (415 ) (1,238 ) (39,830 ) (175,502 ) (40,245 ) (176,740 ) Cumulative adjustment to Retained Earnings (1) $ — $ (1,970 ) $ — $ — $ — $ — $ — $ (1,970 ) Balance at December 31, 2018 $ — $ — $ (7,980 ) $ (7,980 ) $ (159,045 ) $ (159,045 ) $ (167,025 ) $ (167,025 ) (1) As a result of the adoption of ASC 2016-01 we recorded a cumulative effect adjustment to our opening fiscal 2019 retained earnings balance that increased retained earnings and decreased accumulated other comprehensive income. See Footnote 1 titled "Nature of Operations and Summary of Significant Accounting Policies" for further details. (2) Amortization (gain) of defined benefit plan items are reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Currency Translation (3) Total Accumulated Other Comprehensive Income Three Months Nine Months Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ 1,949 $ 178 $ (3,163 ) $ (2,355 ) $ (78,845 ) $ (238,525 ) $ (80,059 ) $ (240,702 ) Other Comprehensive Income (Loss) before reclassifications 2,729 4,474 120 360 22,742 182,422 25,591 187,256 Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 9 35 (524 ) (1,572 ) — — (515 ) (1,537 ) Net current-period Other Comprehensive Income (Loss) 2,738 4,509 (404 ) (1,212 ) 22,742 182,422 25,076 185,719 Balance at December 31, 2017 $ 4,687 $ 4,687 $ (3,567 ) $ (3,567 ) $ (56,103 ) $ (56,103 ) $ (54,983 ) $ (54,983 ) (1) Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) of defined benefit plan items are reported in the Selling, general and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.

Loans Receivable (Notes)

Loans Receivable (Notes)	9 Months Ended
	Dec. 31, 2018
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Loans Receivable In connection with a fiscal 2019 first quarter equity investment of $4,955 , we agreed to provide a credit facility of up to approximately $10,000 for a term of up to five years. Loans carry an interest rate of 4% compounded daily and interest is payable annually. Outstanding borrowings under the agreement totaled $7,338 at December 31, 2018 . In connection with the fiscal 2017 divestiture of Synergy Health Netherlands Linen Management Services, we entered into a loan agreement to provide financing of up to €15,000 for a term of up to 15 years. Loans carry an interest rate of 4% for the first four years and 12% thereafter. Outstanding borrowings under the agreement totaled $8,664 (or €7,550 ) at December 31, 2018 . Amounts for loan receivables as noted above are recorded in the "Other assets" line of our Consolidated balance sheets. Interest income is not material.

Proposal to Redomicile (Notes)

Proposal to Redomicile (Notes)	9 Months Ended
	Dec. 31, 2018
Proposal to Redomicile [Abstract]
Proposal to Redomicile [Text Block]	Proposal to Redomicile As a result of the anticipated withdrawal of the United Kingdom from the European Union (“Brexit”), entities such as the Company that are organized under the laws of England and Wales are expected to lose the benefit of the tax and other treaties between the U.S. and European Union ("EU").Without further action by the United Kingdom and U.S. governments, the Company may consequently be subject to higher tax liabilities, which may be significant. We have evaluated several alternatives due to Brexit’s continuing risks and uncertainties and concluded that redomiciling the Company to Ireland is the best path forward. Maintaining the Company’s domicile in a EU member country is anticipated to preserve the current and significant future financial benefits initially established in 2015 at the time of the Combination with Synergy. The redomiciliation will be effected through the establishment of a new holding company for the Company, but the redomiciliation is not expected to materially change the day-to-day operations of the business. We anticipate completing the redomiciliation prior to March 29, 2019, which is the date Brexit is currently scheduled to occur. However, the proposal is subject to approval by the Company’s shareholders and the English courts, and it is possible that the redomiciliation may be delayed or not occur.

Restructuring (Notes)

Restructuring (Notes)	9 Months Ended
	Dec. 31, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	2. Restructuring Fiscal 2019 Restructuring Plan During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "2019 Restructuring Plan"), which includes the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including, the rationalization of certain products. Fewer than 200 positions will be eliminated. The Company will relocate the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions are designed to enhance profitability and improve efficiency. We have incurred pre-tax expenses totaling $35,243 related to these restructuring actions, of which $26,147 was recorded as restructuring expenses and $9,096 was recorded in cost of revenues, with restructuring expenses of $23,308 , $2,436 , $665 , and $7,805 related to the Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies segments, respectively. Corporate related restructuring charges were $1,029 . We expect to incur additional restructuring expenses related to this plan of approximately $6,000 to $7,000 in the fourth quarter of fiscal 2019 and beyond. The following table summarizes our total pre-tax restructuring expenses for the third quarter of fiscal 2019: Three and Nine Months Ended December 31, 2018 Fiscal 2019 Restructuring Plan (1) Severance and other compensation related costs $ 2,743 Accelerated depreciation and amortization 15,251 Asset impairment 4,312 Lease termination costs and other 3,841 Product rationalization 9,096 Total restructuring expenses (1) $ 35,243 (1) Includes $9,096 in expense recorded to cost of revenues on Consolidated Statements of Income. Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The following table summarizes our restructuring liability balances: Fiscal 2019 Restructuring Plan December 31, Severance and termination benefits $ (2,504 ) Lease termination obligations and other (1,819 ) Total $ (4,323 ) (1) Certain amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.
Use of Estimates	Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2018 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2019.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition and Associated Liabilities We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018 using the modified retrospective approach to contracts that were not completed as of April 1, 2018. Under this standard, certain capital equipment contracts are comprised of a single performance obligation, resulting in the deferral of the corresponding capital equipment revenue and cost of revenues until installation is complete. Previously, these capital equipment revenues and cost of revenues were recognized based upon shipping terms. We recorded a cumulative effect adjustment in the beginning of fiscal 2019 to Retained earnings of $5,637 , based on the current terms and conditions for certain open capital equipment contracts as of March 31, 2018. The impact of the adoption of this standard on our Consolidated Balance Sheets at December 31, 2018 is reflected in the table below. The adoption of this standard did not have a material impact on our Consolidated Statements of Income for the quarter-to-date and year-to-date periods ending December 31, 2018 . Comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. As Reported December 31, Total ASC 605 December 31, Balance Sheet 2018 Adjustments 2018 Total assets $ 5,006,390 $ (7,714 ) $ 4,998,676 Total liabilities 1,894,083 (13,809 ) 1,880,274 Total equity 3,112,307 6,095 3,118,402 Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2018 , assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements. Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to certain capital equipment products is deferred until installation is complete as the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare Products and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancelable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Healthcare Specialty Services segment, revenues relate primarily to outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2019, we recognized revenue of $25,590 that was included in our contract liability balance at the beginning of the period. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances. Service Liabilities Payments received in advance of performance for cancelable preventative maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Prior to the adoption of Accounting Standards Codification ("ASC") 606, these amounts were included in Deferred revenues. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31, 2018 , the transaction price allocated to remaining performance obligations was approximately $780,000 . We expect to recognize approximately 53% of the transaction price within one year and approximately 39% beyond one year. The remainder has yet to be scheduled for delivery.
Recently Issued Accounting Standards Impacting the Company	Recently Issued Accounting Standards impacting or that may impact the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2014-09, "Revenue from Contracts with Customers" and subsequently issued amendments May 2014 The standard replaced existing revenue recognition standards and significantly expands the disclosure requirements for revenue arrangements. First Quarter Fiscal 2019 Additional information is disclosed in Footnote 1 under the heading, "Revenue Recognition and Associated Liabilities". ASU 2016-01, "Financial Instruments - Overall - Recognition and Measurement of Financial Assets and Liabilities" (Subtopic 825-10) January 2016 The standard changed how equity investments are measured and presented changes in the fair value of financial liabilities measured under the fair value option. Presentation and disclosure requirements for financial instruments were also affected. Entities are required to measure equity investments that do not result in consolidation and are not recorded under the equity method at fair value with changes in fair value recognized in net income. The standard clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. First Quarter Fiscal 2019 We adopted the standard on a modified retrospective basis at the beginning of fiscal 2019 and we recorded a cumulative effect adjustment to our opening retained earnings balance of $1,970 that increased retained earnings and decreased accumulated other comprehensive income. ASU 2016-15, "Statement of Cash Flows" (Topic 230) August 2016 This standard provides guidance on the following specific cash flow issues: Debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, beneficial interests in securitization transactions, and separately identifiable cash flows and application of the predominance principle. First Quarter Fiscal 2019 We adopted this standard effective April 1, 2018. The impact will depend on the future occurrence of the relevant transactions or conditions addressed by the standard. ASU 2016-16, "Income Taxes, Intra-Entity Transfers of Assets Other Than Inventory" (Topic 740) October 2016 The standard improves the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. The new standard requires the recognition of income tax consequences resulting from an intra-entity transfer of an asset other than inventory when the transfer occurs. First Quarter Fiscal 2019 We adopted this standard effective April 1, 2018 with no material impact to our Consolidated Balance Sheets. The impact to our Consolidated Statements of Income will depend on the value of future intra-entity transfers. ASU 2017-01 "Clarifying the Definition of a Business" January 2017 The standard update narrows the definition of a business by providing a screen to determine when an integrated set of assets and activities is not a business. The screen specifies that an integrated set of assets and activities is not a business if substantially all of the fair value of the gross assets acquired or disposed of is concentrated in a single or a group of similar identifiable assets. First Quarter Fiscal 2019 We adopted this standard effective April 1, 2018. The impact will depend on the future occurrence of the relevant transactions or conditions addressed by the standard. ASU 2017-07 "Compensation - Retirement Benefits - Improving the Presentation of Net Periodic Pension and Net Periodic Postretirement Benefit Cost" (Topic 715) March 2017 This standard requires that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside the subtotal of income from operations, if one is presented. First Quarter Fiscal 2019 We retrospectively adopted the standard in the first quarter of fiscal 2019. Prior periods have been recast for the adoption of this standard. Changes have been reflected in the Cost of Revenues, Selling, general and administrative expense, and Interest income and miscellaneous expense lines of our Consolidated Statements of Income. Amounts are not considered material for additional disclosure. ASU 2017-09 "Compensation - Stock Compensation" (Topic 718) May 2017 The standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. First Quarter Fiscal 2019 We adopted this standard effective April 1, 2018. The impact will depend on the future occurrence of the relevant terms or conditions addressed by the standard. Standards that have not yet been adopted ASU 2016-02, "Leases" (Topic 842) February 2016 The standard will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted. N/A We are currently evaluating the impact that the standard will have on our consolidated financial statements. We are also evaluating our lease portfolio, software packages, process and policy change requirements. We expect to adopt this standard using the additional, optional transition method, the package of transitional practical expedients relating to the identification, classification and initial direct costs of leases, and the transitional practical expedient for the treatment of existing land easements. We anticipate that most of our operating leases will result in the recognition of additional assets and corresponding liabilities in our Consolidated Balance Sheet, however we do not expect the standard to have a material impact on our financial position. The actual impact will depend on our lease portfolio at the time of adoption. For more information regarding our total operating lease commitments refer to Note 5, "Property, Plant and Equipment" of our Annual Report on Form 10-K for the year ended March 31, 2018 dated May 30, 2018. ASU 2016-13, "Measurement of Credit Losses on Financial Instruments" June 2016 The standard requires a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard is effective for annual periods beginning after December 15, 2019. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. ASU 2017-12 "Targeted Improvements to Accounting for Hedging Activities" (Topic 815) August 2017 The standard provides targeted improvements to accounting for hedging activities by expanding an entity’s ability to hedge non-financial and financial risk components and reduce complexity in fair value hedges of interest rate risk. The guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally requires the entire change in the fair value of a hedging instrument to be presented in the same income statement line as the hedged item. The guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted in any interim period after issuance of the standard. The standard should be applied using a modified retrospective approach for cash flow and net investment hedge relationships that exist on the date of adoption, and prospectively for presentation and disclosure requirements. N/A We do not expect this standard to have a material impact on our consolidated financial statements. ASU 2018-02 "Income Statement - Reporting Comprehensive Income" (Topic 220) February 2018 The standard allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act ("TCJA") and requires certain disclosures about stranded tax effects. The underlying guidance requiring that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. This standard is effective for fiscal years beginning after December 15, 2018 and interim periods within those years. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement” August 2018 The standard modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements as it modifies disclosure requirements only. ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans" August 2018 The standard modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans. The standard also clarifies disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation. The standard is effective for fiscal years ending after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements as it modifies disclosure requirements only. ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract" August 2018 The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for fiscal years ending after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies Rev 606 (Tables)	9 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Impact of ASC 2014-09 Adoption [Table Text Block]	As Reported December 31, Total ASC 605 December 31, Balance Sheet 2018 Adjustments 2018 Total assets $ 5,006,390 $ (7,714 ) $ 4,998,676 Total liabilities 1,894,083 (13,809 ) 1,880,274 Total equity 3,112,307 6,095 3,118,402

Inventories, Net Inventories, N

Inventories, Net Inventories, Net (Tables)	9 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: December 31, March 31, Raw materials $ 88,413 $ 83,741 Work in process 31,238 34,904 Finished goods 146,121 124,005 LIFO reserve (17,800 ) (17,280 ) Reserve for excess and obsolete inventory (20,346 ) (19,639 ) Inventories, net $ 227,626 $ 205,731

Property, Plant and Equipment P

Property, Plant and Equipment Property, Plant and Equipment (Tables)	9 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 64,000 $ 55,417 Buildings and leasehold improvements 427,889 449,316 Machinery and equipment 591,905 575,607 Information systems 156,674 145,726 Radioisotope 486,866 476,578 Construction in progress (1) 130,142 87,745 Total property, plant, and equipment 1,857,476 1,790,389 Less: accumulated depreciation and depletion (868,432 ) (779,865 ) Property, plant, and equipment, net $ 989,044 $ 1,010,524 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Tables)

Debt Debt (Tables)	9 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Schedule of Debt	Indebtedness was as follows: December 31, March 31, Credit Agreement $ 364,853 $ 331,206 Private Placement Notes 884,409 988,190 Deferred financing costs (3,008 ) (3,395 ) Other 54 — Total long term debt $ 1,246,308 $ 1,316,001

Additional Consolidated Balan_2

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables)	9 Months Ended
	Dec. 31, 2018
Notes To Financial Statements [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 26,065 $ 30,270 Accrued vacation/paid time off 11,514 11,011 Accrued bonuses 23,628 31,716 Accrued employee commissions 14,681 17,168 Other postretirement benefit obligations-current portion 1,907 1,906 Other employee benefit plans obligations-current portion 1,803 1,929 Total accrued payroll and other related liabilities $ 79,598 $ 94,000 Accrued expenses and other: Deferred revenues $ 58,827 $ 31,621 Service liabilities 41,549 43,077 Self-insured risk reserves-current portion 8,082 7,349 Accrued dealer commissions 14,016 16,121 Accrued warranty 7,116 6,872 Asset retirement obligation-current portion 1,763 1,798 Other 50,345 61,379 Total accrued expenses and other $ 181,698 $ 168,217 Other liabilities: Self-insured risk reserves-long-term portion $ 15,008 $ 15,008 Other postretirement benefit obligations-long-term portion 10,350 12,194 Defined benefit pension plans obligations-long-term portion 24,146 29,407 Other employee benefit plans obligations-long-term portion 2,551 3,221 Accrued long-term income taxes 16,546 18,922 Asset retirement obligation-long-term portion 9,484 9,841 Other 18,513 20,007 Total other liabilities $ 96,598 $ 108,600

Business Segment Information Bu

Business Segment Information Business Segment Information (Tables)	9 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Financial information for each of our segments is presented in the following table: Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 Revenues: Healthcare Products $ 338,264 $ 324,895 $ 951,779 $ 916,053 Healthcare Specialty Services 127,761 117,389 374,564 346,934 Life Sciences 93,451 90,895 275,571 261,291 Applied Sterilization Technologies 136,762 128,721 412,043 379,745 Total revenues $ 696,238 $ 661,900 $ 2,013,957 $ 1,904,023 Segment operating income: Healthcare Products $ 82,820 $ 81,502 $ 217,011 $ 207,787 Healthcare Specialty Services 16,007 13,720 44,422 44,014 Life Sciences 33,129 31,245 96,260 89,418 Applied Sterilization Technologies 54,798 48,191 164,417 144,713 Corporate (42,025 ) (38,140 ) (135,053 ) (122,147 ) Total segment operating income $ 144,729 $ 136,518 $ 387,057 $ 363,785 Less: Adjustments Restructuring charges (1) $ 35,243 $ 78 $ 35,243 $ 156 Amortization of acquired intangible assets (2) (3) 33,894 16,700 68,907 50,173 Acquisition and integration related charges (4) 1,816 4,428 6,197 11,850 (Gain) on fair value adjustment of acquisition related contingent consideration (2) — — (842 ) — Net (gain) loss on divestiture of businesses (2) (1,170 ) 11,405 (508 ) 12,538 Amortization of property "step up" to fair value (2) 615 627 1,840 1,895 Redomiciliation costs (5) 4,747 — 5,633 — Total operating income $ 69,584 $ 103,280 $ 270,587 $ 287,173
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 Healthcare Products: Capital equipment $ 143,180 $ 134,196 $ 384,086 $ 359,196 Consumables 107,451 106,406 309,545 310,938 Service 87,633 84,293 258,148 245,919 Total Healthcare Products Revenues $ 338,264 $ 324,895 $ 951,779 $ 916,053 Total Healthcare Specialty Services Revenues $ 127,761 $ 117,389 $ 374,564 $ 346,934 Life Sciences: Capital equipment $ 23,363 $ 25,337 $ 72,289 $ 67,093 Consumables 41,157 37,875 119,844 113,833 Service 28,931 27,683 83,438 80,365 Total Life Sciences Revenues $ 93,451 $ 90,895 $ 275,571 $ 261,291 Applied Sterilization Technologies Service Revenues $ 136,762 $ 128,721 $ 412,043 $ 379,745 Total Revenues $ 696,238 $ 661,900 $ 2,013,957 $ 1,904,023
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 Revenues: United Kingdom $ 46,067 $ 50,902 $ 138,074 $ 158,211 United States 494,328 465,228 1,423,101 1,334,895 Other locations 155,843 145,770 452,782 410,917 Total Revenues $ 696,238 $ 661,900 $ 2,013,957 $ 1,904,023

Shares and Preferred Shares Sha

Shares and Preferred Shares Shares and Preferred Shares (Tables)	9 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, Denominator (shares in thousands): 2018 2017 2018 2017 Weighted average shares outstanding—basic 84,540 85,004 84,587 85,097 Dilutive effect of share equivalents 901 715 889 672 Weighted average shares outstanding and share equivalents—diluted 85,441 85,719 85,476 85,769
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended December 31, Nine Months Ended December 31, (shares in thousands) 2018 2017 2018 2017 Number of share options 435 294 331 426

Share-Based Compensation Share-

Share-Based Compensation Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Assumptions Used	The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2019 and 2018: Fiscal 2019 Fiscal 2018 Risk-free interest rate 2.64% 2.01% Expected life of options 6.2 years 5.7 years Expected dividend yield of stock 1.47% 1.58% Expected volatility of stock 19.91% 22.08%
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2018 2,021,662 $ 58.56 Granted 436,121 114.49 Exercised (191,995 ) 40.05 Forfeited (17,740 ) 79.91 Outstanding at December 31, 2018 2,248,048 $ 70.83 6.8 years $ 84,291 Exercisable at December 31, 2018 1,307,946 $ 56.03 5.5 years $ 66,631
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the non-vested restricted share and restricted share unit activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2018 763,201 35,431 $ 68.85 Granted 177,558 19,858 104.84 Vested (233,095 ) (21,540 ) 62.12 Forfeited (30,469 ) — 76.62 Non-vested at December 31, 2018 677,195 33,749 $ 80.72

Financial and Other Guarantees

Financial and Other Guarantees Financial and Other Gurantees (Tables)	9 Months Ended
	Dec. 31, 2018
Product Warranties Disclosures [Abstract]
Schedule of Product Warranty Liability	Changes in our warranty liability during the first nine months of fiscal 2019 were as follows: Warranties Balance, March 31, 2018 $ 6,872 Warranties issued during the period 8,393 Settlements made during the period (8,149 ) Balance, December 31, 2018 $ 7,116

Derivatives and Hedging Derivat

Derivatives and Hedging Derivatives and Hedging (Tables)	9 Months Ended
	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location December 31, 2018 March 31, 2018 December 31, 2018 March 31, 2018 Prepaid & Other $ 267 $ 187 $ — $ — Accrued expenses and other — — 462 —
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) recognized in income Amount of gain (loss) recognized in income Three Months Ended December 31, Nine Months Ended December 31, 2018 2017 2018 2017 Foreign currency forward contracts Selling, general and administrative $ (488 ) $ (842 ) $ (100 ) $ (1,358 ) Commodity swap contracts Cost of revenues $ (252 ) $ 200 $ (283 ) $ 226

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements (Tables)	9 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table shows the fair value of our financial assets and liabilities at December 31, 2018 and March 31, 2018 : Fair Value Measurements Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 December 31 March 31 December 31 March 31 December 31 March 31 December 31 March 31 Assets: Cash and cash equivalents $ 224,906 $ 201,534 $ 224,906 $ 201,534 $ — $ — $ — $ — Forward and swap contracts (1) 267 187 — — 267 187 — — Equity Investments (2) $ 11,824 12,961 11,824 12,961 — — — — Other investments 2,010 3,421 1 2,010 3,421 — — — — — — Liabilities: Forward and swap contracts (1) $ 462 $ — $ — $ — $ 462 $ — $ — $ — Deferred compensation plans (2) 1,505 1,694 1,505 1,694 — — — — Long term debt (3) $ 1,246,308 1,316,001 — — 1,227,345 1,305,181 — — Contingent consideration obligations (4) 5,947 8,068 — — — — 5,947 8,068
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2018 are summarized as follows: Contingent Consideration Balance at March 31, 2018 $ 8,068 Payments (725 ) Reductions and adjustments (1,415 ) Currency translation adjustments 19 Balance at December 31, 2018 $ 5,947

Reclassifications out of Accu_2

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Dec. 31, 2018
Reclassifications out of AOCI [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2018 and 2017 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Currency Translation (3) Total Accumulated Other Comprehensive Income Three Months Nine Months Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ — $ 1,970 $ (7,565 ) $ (6,742 ) $ (119,215 ) $ 16,457 $ (126,780 ) $ 11,685 Other Comprehensive Income (Loss) before reclassifications — — 148 452 (39,830 ) (175,502 ) (39,682 ) (175,050 ) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) — — (563 ) (1,690 ) — — (563 ) (1,690 ) Net current-period Other Comprehensive Income (Loss) — — (415 ) (1,238 ) (39,830 ) (175,502 ) (40,245 ) (176,740 ) Cumulative adjustment to Retained Earnings (1) $ — $ (1,970 ) $ — $ — $ — $ — $ — $ (1,970 ) Balance at December 31, 2018 $ — $ — $ (7,980 ) $ (7,980 ) $ (159,045 ) $ (159,045 ) $ (167,025 ) $ (167,025 ) (1) As a result of the adoption of ASC 2016-01 we recorded a cumulative effect adjustment to our opening fiscal 2019 retained earnings balance that increased retained earnings and decreased accumulated other comprehensive income. See Footnote 1 titled "Nature of Operations and Summary of Significant Accounting Policies" for further details. (2) Amortization (gain) of defined benefit plan items are reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Currency Translation (3) Total Accumulated Other Comprehensive Income Three Months Nine Months Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ 1,949 $ 178 $ (3,163 ) $ (2,355 ) $ (78,845 ) $ (238,525 ) $ (80,059 ) $ (240,702 ) Other Comprehensive Income (Loss) before reclassifications 2,729 4,474 120 360 22,742 182,422 25,591 187,256 Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 9 35 (524 ) (1,572 ) — — (515 ) (1,537 ) Net current-period Other Comprehensive Income (Loss) 2,738 4,509 (404 ) (1,212 ) 22,742 182,422 25,076 185,719 Balance at December 31, 2017 $ 4,687 $ 4,687 $ (3,567 ) $ (3,567 ) $ (56,103 ) $ (56,103 ) $ (54,983 ) $ (54,983 ) (1) Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) of defined benefit plan items are reported in the Selling, general and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The following table summarizes our total pre-tax restructuring expenses for the third quarter of fiscal 2019: Three and Nine Months Ended December 31, 2018 Fiscal 2019 Restructuring Plan (1) Severance and other compensation related costs $ 2,743 Accelerated depreciation and amortization 15,251 Asset impairment 4,312 Lease termination costs and other 3,841 Product rationalization 9,096 Total restructuring expenses (1) $ 35,243 (1) Includes $9,096 in expense recorded to cost of revenues on Consolidated Statements of Income.
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The following table summarizes our restructuring liability balances: Fiscal 2019 Restructuring Plan December 31, Severance and termination benefits $ (2,504 ) Lease termination obligations and other (1,819 ) Total $ (4,323 ) (1) Certain amounts reported include the impact of foreign currency movements relative to the U.S. dollar

Nature of Operations and Summ_4

Nature of Operations and Summary of Significant Accounting Policies table (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2018	Apr. 01, 2018	Mar. 31, 2018
Property, Plant and Equipment [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 780,000
Assets	5,006,390		$ 5,200,334
Liabilities	1,894,083		1,983,034
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,112,307		$ 3,217,300
Deferred Revenue, Revenue Recognized	$ 25,590
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Assets [Member]
Property, Plant and Equipment [Line Items]
Cumulative Effect of New Accounting Principle in Period of Adoption	$ (7,714)
Balance Sheet Item under ASC 605	4,998,676
Equity [Member]
Property, Plant and Equipment [Line Items]
Cumulative Effect of New Accounting Principle in Period of Adoption	6,095	$ 5,637
Balance Sheet Item under ASC 605	3,118,402
Liabilities, Total [Member]
Property, Plant and Equipment [Line Items]
Cumulative Effect of New Accounting Principle in Period of Adoption	(13,809)
Balance Sheet Item under ASC 605	$ 1,880,274
Expected recognition within the next year [Member]
Property, Plant and Equipment [Line Items]
Revenue, Remaining Performance Obligation, Percentage	53.00%
Expected recognition beyond the next year [Member] [Member]
Property, Plant and Equipment [Line Items]
Revenue, Remaining Performance Obligation, Percentage	39.00%

Business Acquisitions and Div_2

Business Acquisitions and Divestitures Fiscal 2018 Acquisitions (Details) - USD ($)	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Contingent consideration	$ 5,947,000	$ 8,068,000
Fiscal 2018 [Member] [Member]
Business Acquisition [Line Items]
Purchase price of acquired entity		5,322,000
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Approximate purchase price of entity	$ 13,313,000	$ 52,900,000	$ 51,600,000

Business Acquisitions and Div_3

Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Revenues	$ 696,238	$ 661,900	$ 2,013,957	$ 1,904,023

Business Acquisitions and Div_4

Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended			12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2018	Mar. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues		$ 696,238	$ 661,900	$ 2,013,957	$ 1,904,023
Proceeds from sale of business				196	(8,907)
Pre-tax gain or loss on sale of business	[1]	$ (1,170)	$ (11,405)	$ (508)	$ 12,538
Years 1-4, 4% Int Rate
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest rate								4.00%
Years 5-15, 12% Int Rate
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest rate								12.00%
HCS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues						$ 40,000
Proceeds from sale of business							$ (9,058)
HCS [Member] | Selling, general, and administrative expense
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax gain or loss on sale of business							$ 13,500
[1]	For more information regarding our recent acquisitions and divestitures see Note 17 titled, "Business Acquisitions and Divestitures", as well as our Annual Report on Form 10-K for the year ended March 31, 2018, dated May 30, 2018.

Inventories, Net Inventories,_2

Inventories, Net Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Mar. 31, 2018
Raw materials	$ 88,413	$ 83,741
Work in process	31,238	34,904
Finished goods	146,121	124,005
LIFO reserve	(17,800)	(17,280)
Reserve for excess and obsolete inventory	(20,346)	(19,639)
Inventories, net	$ 227,626	$ 205,731

Property, Plant and Equipment_2

Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($) $ in Thousands		3 Months Ended
		Dec. 31, 2018		Mar. 31, 2018
Property, Plant and Equipment [Line Items]
Asset Impairment Charges		$ 16,249
Land and land improvements		64,000	[1]	$ 55,417
Buildings and leasehold improvements		427,889		449,316
Machinery and equipment		591,905		575,607
Information systems		156,674		145,726
Radioisotope		486,866		476,578
Construction in progress	[1]	130,142		87,745
Total property, plant, and equipment		1,857,476		1,790,389
Less: accumulated depreciation and depletion		(868,432)		(779,865)
Property, plant, and equipment, net		$ 989,044		$ 1,010,524
[1]	Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Details)

Debt Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Private Placement	$ 884,409	$ 988,190
Deferred financing costs	3,008	3,395
Other Long-term Debt, Noncurrent	54	0
Credit Agreement	364,853	331,206
Total long term debt	$ 1,246,308	$ 1,316,001

Additional Consolidated Balan_3

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Mar. 31, 2018
Accrued payroll and other related liabilities:
Compensation and related items	$ 26,065	$ 30,270
Accrued vacation/paid time off	11,514	11,011
Accrued bonuses	23,628	31,716
Accrued employee commissions	14,681	17,168
Other postretirement benefit obligations-current portion	1,907	1,906
Other employee benefit plans obligations-current portion	1,803	1,929
Total accrued payroll and other related liabilities	79,598	94,000
Accrued expenses and other:
Deferred revenues	58,827	31,621
Service liabilities	41,549	43,077
Self-insured risk reserves-current portion	8,082	7,349
Accrued dealer commissions	14,016	16,121
Accrued warranty	7,116	6,872
Asset retirement obligation-current portion	1,763	1,798
Other	50,345	61,379
Total accrued expenses and other	181,698	168,217
Other liabilities:
Self-insured risk reserves-long-term portion	15,008	15,008
Other postretirement benefit obligations-long-term portion	10,350	12,194
Defined benefit pension plans obligations-long-term portion	24,146	29,407
Other employee benefit plans obligations-long-term portion	2,551	3,221
Accrued long-term income taxes	16,546	18,922
Asset retirement obligation-long-term portion	9,484	9,841
Other	18,513	20,007
Total other liabilities	$ 96,598	$ 108,600

Income Tax Expense Income Tax E

Income Tax Expense Income Tax Expense (Details)	3 Months Ended				9 Months Ended
	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%		35.00%
Effective Income Tax Rate, Continuing Operations	16.20%		(3.70%)		16.90%	14.00%

Business Segment Information _2

Business Segment Information Business Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
		Dec. 31, 2018		Dec. 31, 2017	Dec. 31, 2018		Dec. 31, 2017
Segment Reporting Information [Line Items]
Asset Impairment Charges		$ 16,249
Revenues		696,238		$ 661,900	$ 2,013,957		$ 1,904,023
Segment operating income		69,584		103,280	270,587		287,173
Restructuring Charges	[1]	35,243		78	35,243	[2]	156
Amortization of acquired intangible assets	[3]	33,894	[4]	16,700	68,907	[4]	50,173
Acquisition and integration related charges	[5]	1,816		4,428	6,197		11,850
loss (gain) on fair value contingent consideration adjustments	[3]	0		0	(842)
Net loss on divestiture of businesses	[3]	(1,170)		(11,405)	(508)		12,538
Amortization of inventory and property step-up to fair value	[3]	615		627	1,840		1,895
Goodwill, Impairment Loss	[6]	4,747		0	5,633		0
Healthcare Products
Segment Reporting Information [Line Items]
Revenues		338,264		324,895	951,779		916,053
Segment operating income		82,820		81,502	217,011		207,787
Restructuring Charges					23,308
Healthcare Specialty Services
Segment Reporting Information [Line Items]
Revenues		127,761		117,389	374,564		346,934
Segment operating income		16,007		13,720	44,422		44,014
Restructuring Charges					2,436
Life Sciences
Segment Reporting Information [Line Items]
Revenues		93,451		90,895	275,571		261,291
Segment operating income		33,129		31,245	96,260		89,418
Restructuring Charges					665
Applied Sterilization Technologies
Segment Reporting Information [Line Items]
Revenues		136,762		128,721	412,043		379,745
Segment operating income		54,798		48,191	164,417		144,713
Restructuring Charges					7,805
Corporate
Segment Reporting Information [Line Items]
Segment operating income		(42,025)		(38,140)	(135,053)		(122,147)
Segment operating income
Segment Reporting Information [Line Items]
Revenues		696,238		661,900	2,013,957		1,904,023
Segment operating income		144,729		136,518	387,057		363,785
UNITED KINGDOM
Segment Reporting Information [Line Items]
Revenues		46,067		50,902	138,074		158,211
UNITED STATES
Segment Reporting Information [Line Items]
Revenues		494,328		465,228	1,423,101		1,334,895
Other foreign locations [Member]
Segment Reporting Information [Line Items]
Revenues		155,843		145,770	452,782		410,917
Capital equipment revenues [Member] | Healthcare Products
Segment Reporting Information [Line Items]
Revenues		143,180		134,196	384,086		359,196
Capital equipment revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		23,363		25,337	72,289		67,093
Consumable revenues [Member] | Healthcare Products
Segment Reporting Information [Line Items]
Revenues		107,451		106,406	309,545		310,938
Consumable revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		41,157		37,875	119,844		113,833
Service revenues [Member] | Healthcare Products
Segment Reporting Information [Line Items]
Revenues		87,633		84,293	258,148		245,919
Service revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		$ 28,931		$ 27,683	$ 83,438		$ 80,365
[1]	For more information regarding restructuring see Note 2 titled, "Restructuring".
[2]	(1) Includes $9,096 in expense recorded to cost of revenues on Consolidated Statements of Income.
[3]	For more information regarding our recent acquisitions and divestitures see Note 17 titled, "Business Acquisitions and Divestitures", as well as our Annual Report on Form 10-K for the year ended March 31, 2018, dated May 30, 2018.
[4]	We evaluate the recoverability of indefinite-lived assets annually during the third quarter, or when evidence of potential impairment exists. During the third quarter of fiscal 2019, management adopted a branding strategy that included phasing out the usage of a tradename associated with certain products in the Healthcare Products business segment. As a result, management recorded an impairment charge of $16,249, which is included within the Selling, general, and administrative line of the Consolidated Statements of Income. The remaining fair value of the asset was calculated using the income approach (the relief from royalty method). The remaining fair value was not material and will be amortized over the asset's remaining useful life.
[5]	Acquisition and integration related charges include transaction costs and integration expenses associated with acquisition
[6]	Costs incurred in connection with the proposal to redomicile. For more information see Note 19 titled, "Proposal to Redomicile".

Shares and Preferred Shares Ord

Shares and Preferred Shares Ordinary Shares (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average shares outstanding - basic	84,540	85,004	84,587	85,097
Dilutive effect of share equivalents	901	715	889	672
Weighted average shares outstanding and share equivalents - diluted	85,441	85,719	85,476	85,769
Employee share option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of share options that are antidilutive	435	294	331	426

Shares and Preferred Shares Pre

Shares and Preferred Shares Preferred Shares (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2018£ / shares	Dec. 31, 2018USD ($)shares	Mar. 31, 2018£ / shares	Mar. 31, 2018USD ($)shares	Oct. 23, 2015£ / shares	Oct. 23, 2015USD ($)shares
Class of Stock [Line Items]
Preferred shares, shares issued | shares		100,000		100,000		100,000
Preferred shares, par value	£ 0.10		£ 0.10
Preferred shares, value issued | $		$ 15		$ 15
Preferred shares, annual dividend rate	5.00%
United States of America, Dollars
Class of Stock [Line Items]
Preferred shares, value issued | $						$ 15
United Kingdom, Pounds
Class of Stock [Line Items]
Preferred shares, par value					£ 0.10
Preferred shares, redemption price per share					£ 0.10

Repurchases of Shares Repurchas

Repurchases of Shares Repurchases of Shares (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2018	Aug. 09, 2016
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, number of shares authorized		$ 300,000
Shares repurchased during period, number	445,700
Aggregate value of shares repurchased pursuant to authorization	$ 47,331
Shares obtained in connection with share based compensation award programs	110,445
Payments for shares obtained in connection with share based compensation programs	$ 8,151

Share-Based Compensation Shar_2

Share-Based Compensation Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	4,401,238
Weighted-average assumptions used for options granted:
Risk-free interest rate	2.64%	2.01%
Expected life of options	6 years 2 months 27 days	5 years 8 months 16 days
Exptected dividend yield of stock	1.47%	1.58%
Expected volatility of stock	19.91%	22.08%
Estimated forfeiture rate	2.37%	2.25%
Summary of share option activity:
Outstanding at March 31, 2017	2,021,662
Granted	436,121
Exercised	(191,995)
Forfeited	(17,740)
Outstanding at June 30, 2017	2,248,048
Exercisable at June 30, 2017	1,307,946
Weighted average exercise price:
Outstanding at March 31, 2017	$ 58.56
Granted	114.49
Exercised	40.05
Forfeited	79.91
Outstanding at June 30, 2017	70.83
Exercisable at June 30, 2017	$ 56.03
Average Remaining Contractual Term, Outstanding at June 30, 2017	6 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding at June 30, 2017	$ 84,291
Average Remaining Contractual Term, Exercisable at June 30, 2017	5 years 6 months
Aggregate Intrinsic Value, Exercisable at June 30, 2017	$ 66,631
Non-vested stock options outstanding expected to vest	919,536
Ordinary shares, closing price	$ 106.85
Total intrinsic value of stock options exercised	$ 13,773	$ 12,495
Net cash proceeds from the exercise of stock options	$ 7,534	$ 9,080
Weighted average grant date fair value of stock option grants, per share	$ 18.12	$ 15.51
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 43,979
Weighted Average Period For Total Compensation Expense Not Yet Recognized	2 years 2 months 9 days
Stock Appreciation Rights (SARs) [Member]
Weighted average exercise price:
FairValueOfOutstandingStockAppreciationRights	$ 692	$ 1,733
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	763,201
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 68.85
Number of Restricted Shares, Granted	177,558
Weighted-Average Grant Date Fair Value, Granted	$ 104.84
Number of Restricted Shares, Vested	(233,095)
Weighted-Average Grant Date Fair Value, Vested	$ 62.12
Number of Restricted Shares, Canceled	(30,469)
Weighted-Average Grant Date Fair Value, Canceled	$ 76.62
Number of Restricted Shares, Non-vested at End of Period	677,195
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 80.72
Fair Value, Share-based Payment Awards, Other than Options	$ 15,817
Restricted Stock Units (RSUs)
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	35,431
Number of Restricted Shares, Granted	19,858
Number of Restricted Shares, Vested	(21,540)
Number of Restricted Shares, Canceled	0
Number of Restricted Shares, Non-vested at End of Period	33,749

Financial and Other Guarantee_2

Financial and Other Guarantees Financial and Other Guarantees (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2018USD ($)
Product Warranty Liability [Line Items]
Balance, March 31, 2017	$ 6,872
Warranties issued during the period	8,393
Settlement made during the period	(8,149)
Balance, June 30, 2017	$ 7,116

Derivatives and Hedging Fair Va

Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) $ in Thousands, € in Millions, $ in Millions, $ in Millions	3 Months Ended
	Dec. 31, 2018USD ($)lb	Dec. 31, 2018CAD ($)	Dec. 31, 2018MXN ($)	Dec. 31, 2018EUR (€)	Mar. 31, 2018USD ($)
Derivative [Line Items]
Non-derivative Net Investment Hedge	$ 52,253
Prepaid & Other
Derivative [Line Items]
Asset derivatives	267				$ 187
Liability derivatives	0				0
Accrued expenses and other
Derivative [Line Items]
Asset derivatives	0				0
Liability derivatives	$ 462				$ 0
Commodity swap contracts
Derivative [Line Items]
Derivative, notional amount, weight | lb	789,900
Mexican peso | Foreign currency forward contracts
Derivative [Line Items]
Derivative, notional amount			$ 152.2
Canadian dollar | Foreign currency forward contracts
Derivative [Line Items]
Derivative, notional amount		$ 8.9
euro | Foreign currency forward contracts
Derivative [Line Items]
Derivative, notional amount | €				€ 2

Derivatives and Hedging Gain (L

Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Foreign currency forward contracts | Selling, general, and administrative expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ (488)	$ (842)	$ (100)	$ (1,358)
Commodity swap contracts | Cost of revenues
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ 252	$ (200)	$ 283	$ (226)

Fair Value Measurements Fair _2

Fair Value Measurements Fair Value Hierarchy (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
		Dec. 31, 2018	Dec. 31, 2018	Mar. 31, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity Securities, FV-NI, Gain (Loss)		$ (2,154)	$ (4,663)
Assets:
Equity Securities, FV-NI	[1]	11,824	11,824	$ 12,961
Liabilities:
Contingent consideration obligations		5,947	5,947	8,068
Level 1
Assets:
Cash and cash equivalents		224,906	224,906	201,534
Forward and swap contracts	[2]	0	0	0
Equity Securities, FV-NI	[1]	11,824	11,824
Investments		2,010	2,010	3,421
Liabilities:
Forward and swap contracts	[2]	0	0	0
Deferred compensation plans	[1]	1,505	1,505	1,694
Long term debt	[3]	0	0	0
Contingent consideration obligations	[4]	0	0	0
Level 2
Assets:
Cash and cash equivalents		0	0	0
Forward and swap contracts	[2]	267	267	187
Equity Securities, FV-NI	[1]	0	0
Investments		0	0	0
Liabilities:
Forward and swap contracts	[2]	462	462	0
Deferred compensation plans	[1]	0	0	0
Long term debt	[3]	1,227,345	1,227,345	1,305,181
Contingent consideration obligations	[4]	0	0	0
Level 3
Assets:
Cash and cash equivalents		0	0	0
Forward and swap contracts	[2]	0	0	0
Investments				0
Liabilities:
Forward and swap contracts	[2]	0	0	0
Deferred compensation plans	[1]	0	0	0
Long term debt	[3]	0	0	0
Contingent consideration obligations	[4]	5,947	5,947	8,068
Carrying Value
Assets:
Cash and cash equivalents		224,906	224,906	201,534
Forward and swap contracts	[2]	267	267	187
Investments		2,010	2,010	3,421
Liabilities:
Forward and swap contracts	[2]	462	462	0
Deferred compensation plans	[1]	1,505	1,505	1,694
Long term debt	[3]	1,246,308	1,246,308	1,316,001
Contingent consideration obligations	[4]	$ 5,947	$ 5,947	$ 8,068
[1]	We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Beginning in fiscal 2019, changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income
[2]	The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[3]	We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
[4]	Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

Fair Value Measurements Conting

Fair Value Measurements Contingent Consideration Rollforward (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2018	Mar. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	$ 5,947	$ 8,068
Contingent consideration gain loss [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration	(1,415)
Payments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration	(725)
Foreign currency translation adjustment
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration	$ 19

Reclassifications out of Accu_3

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended					9 Months Ended
	Dec. 31, 2018		Jun. 30, 2018	Dec. 31, 2017		Dec. 31, 2018		Dec. 31, 2017		Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017		Mar. 31, 2017
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (167,025)			$ (54,983)		$ (167,025)		$ (54,983)		$ (126,780)	$ 11,685	$ (80,059)		$ (240,702)
Other Comprehensive (Loss) Income, Available-for-sale Securities Adjustment, Net of Tax	0			(2,738)		0		(4,509)
Other Comprehensive Income (Loss), Net of Tax	(39,682)			25,591		(175,050)		187,256
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	563			515		1,690		(1,537)
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent	40,245			(25,076)		176,740		(185,719)
Accounting Standards Update 2016-01 [Member]
Reclassifications from AOCI [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	0	[1]	$ (1,970)			(1,970)	[1]
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	(159,045)			(56,103)	[2]	(159,045)		(56,103)	[2]	(119,215)	16,457	(78,845)	[2]	(238,525)	[2]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(39,830)			22,742	[2]	(175,502)		182,422	[2]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	[3]		0	[2]	0	[3]	0	[2]
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent	39,830	[3]		(22,742)	[2]	175,502	[3]	(182,422)	[2]
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	7,980			3,567	[4]	7,980		3,567	[4]	7,565	6,742	3,163	[4]	(2,355)	[4]
Other Comprehensive Income (Loss), Net of Tax	(148)			(120)	[4]	(452)		360	[4]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	563	[5]		524	[4]	1,690	[5]	(1,572)	[4]
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent	415	[5]		404	[4]	1,238	[5]	1,212	[4]
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
Reclassifications from AOCI [Line Items]
Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax	0			4,687	[6]	0		4,687	[6]	$ 0	$ 1,970	$ 1,949	[6]	$ 178	[6]
Other Comprehensive (Loss) Income, Available-for-sale Securities Adjustment, Net of Tax	0			(2,729)	[6]	0		4,474	[6]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0			(9)	[6]	0		(35)	[6]
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent	$ 0			$ (2,738)	[6]	$ 0		$ 4,509	[6]
[1]	As a result of the adoption of ASC 2016-01 we recorded a cumulative effect adjustment to our opening fiscal 2019 retained earnings balance that increased retained earnings and decreased accumulated other comprehensive income. See Footnote 1 titled "Nature of Operations and Summary of Significant Accounting Policies" for further details.
[2]	The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income
[3]	The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
[4]	2) Amortization (gain) of defined benefit plan items are reported in the Selling, general and administrative expense line of the Consolidated Statements of Income.
[5]	Amortization (gain) of defined benefit plan items are reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.
[6]	Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the Consolidated Statements of Income.

Loans Receivable (Details)

Loans Receivable (Details) € in Thousands, $ in Thousands	Dec. 31, 2018USD ($)	Dec. 31, 2018EUR (€)	Jun. 30, 2018USD ($)	Mar. 31, 2017EUR (€)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Investment Owned, at Cost			$ 4,955
Line of Credit Provided to Investee			$ 10,000
Loan Rate 4% [Member] [Domain]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			4.00%
Years 1-4, 4% Int Rate [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				4.00%
Years 5-15, 12% Int Rate [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				12.00%
Equity Investee Loan [Domain]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans Receivable, Net	$ 7,338
Dutch Linen Loan [Domain]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loans Receivable, Net	$ 8,664	€ 7,550
Loan Agreement Max Borrowing Amount Dutch Linen Sale | €				€ 15,000

Restructuring (Details)

Restructuring (Details) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018USD ($)plan		Dec. 31, 2017USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Number of Positions Eliminated | plan				200
Restructuring Reserve	[1]	$ (4,323)		$ (4,323)
Restructuring Costs		26,147	$ 78	26,147		$ 156
Restructuring Charges	[2]	35,243	$ 78	35,243	[3]	$ 156
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve		(2,504)		(2,504)
Restructuring Costs				2,743
Reduced Depreciation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs				15,251
Asset impairment charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs				4,312
Operating Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				26,147
Cost of Goods, Total [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				9,096
Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve		(1,819)		(1,819)
Restructuring Costs				3,841
Product Rationalization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs				9,096
Healthcare Products [Member] [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				23,308
Healthcare Specialty Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				2,436
Life Science Member [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				665
Applied Sterilization Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				7,805
Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				1,029
Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost Remaining		6,000		6,000
Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost Remaining		$ 7,000		$ 7,000
[1]	(1) Certain amounts reported include the impact of foreign currency movements relative to the U.S. dollar
[2]	For more information regarding restructuring see Note 2 titled, "Restructuring".
[3]	(1) Includes $9,096 in expense recorded to cost of revenues on Consolidated Statements of Income.